高流量鼻导管氧疗与标准氧疗对COVID-19呼吸衰竭患者死亡率的影响:SOHO-COVID随机临床试验
SOHO-COVID随机临床试验在法国34个ICU纳入711例COVID-19呼吸衰竭且PaO2/FiO2≤200 mmHg的患者,随机接受高流量鼻导管氧疗(n=357)或标准氧疗(经非重复呼吸面罩,初始最低10 L/min,n=354)。主要终点28天死亡率高流量组10%(36/357) vs 标准氧疗组11%(40/354),绝对差-1.2%(95%CI -5.8%至3.4%),P=0.60,无显著差异。13项预设次要终点中12项无显著差异,包括ICU住院时间和死亡率、90天死亡率;插管率显著降低(45% vs 53%,绝对差-7.7%,95%CI -14.9%至-0.4%,P=0.04)。最常见不良事件为呼吸机相关性肺炎(高流量组58% vs 标准氧疗组53%)。
要点
- 在COVID-19呼吸衰竭且PaO2/FiO2≤200 mmHg的ICU患者中,高流量鼻导管氧疗较标准氧疗未显著降低28天死亡率(10% vs 11%,绝对差-1.2%,95%CI -5.8%至3.4%,P=0.60)。
- 高流量鼻导管氧疗组插管率显著低于标准氧疗组(45% vs 53%,绝对差-7.7%,95%CI -14.9%至-0.4%,P=0.04)。
- 13项预设次要终点中12项无显著差异,包括ICU住院时间和死亡率、90天死亡率。
- 28天无呼吸机天数两组无显著差异(中位数28天[IQR 11-28] vs 23天[IQR 10-28],绝对差0.5天,95%CI -7.7至9.1,P=0.07)。
- 最常见不良事件为呼吸机相关性肺炎,高流量组58%(93/160) vs 标准氧疗组53%(99/186)。
适用人群与场景
- 法国34个ICU收治的COVID-19呼吸衰竭患者,PaO2/FiO2≤200 mmHg,2021年1月至12月入组,末次随访2022年3月5日。
- 共711例纳入分析(平均[SD]年龄61[12]岁;女性214例[30%])。
诊断标准与关键阈值
- 纳入标准:COVID-19呼吸衰竭且PaO2/FiO2≤200 mmHg,收治于ICU。
处置流程与药物剂量
- 高流量鼻导管氧疗组(n=357)接受高流量氧疗。
- 标准氧疗组(n=354)经非重复呼吸面罩给氧,初始最低设置为10 L/min。
研究设计与关键结果
- 研究类型:SOHO-COVID随机临床试验,为正在进行的原SOHO随机临床试验的辅助试验,在法国34个ICU进行,纳入711例COVID-19呼吸衰竭患者。
- 干预与对照:高流量鼻导管氧疗(n=357) vs 标准氧疗(经非重复呼吸面罩,初始最低10 L/min,n=354)。
- 主要终点:28天死亡率高流量组10%(36/357) vs 标准氧疗组11%(40/354),绝对差-1.2%(95%CI -5.8%至3.4%),P=0.60。
- 次要终点:13项预设次要终点中12项无显著差异,包括ICU住院时间和死亡率、90天死亡率;插管率高流量组45%(160/357) vs 标准氧疗组53%(186/354),绝对差-7.7%(95%CI -14.9%至-0.4%),P=0.04;28天无呼吸机天数中位数28天(IQR 11-28) vs 23天(IQR 10-28),绝对差0.5天(95%CI -7.7至9.1),P=0.07。
- 不良事件:最常见为呼吸机相关性肺炎,高流量组58%(93/160) vs 标准氧疗组53%(99/186)。
证据类型、等级与局限
- 证据类型:随机临床试验(RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在COVID-19呼吸衰竭且PaO2/FiO2≤200 mmHg的ICU患者中,高流量鼻导管氧疗较标准氧疗未显著降低28天死亡率,但插管率显著降低。
指南或共识出处
- SOHO-COVID随机临床试验,ClinicalTrials.gov标识符NCT04468126。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The benefit of high-flow nasal cannula oxygen (high-flow oxygen) in terms of intubation and mortality in patients with respiratory failure due to COVID-19 is controversial.
OBJECTIVE: To determine whether the use of high-flow oxygen, compared with standard oxygen, could reduce the rate of mortality at day 28 in patients with respiratory failure due to COVID-19 admitted in intensive care units (ICUs).
DESIGN, SETTING, AND PARTICIPANTS: The SOHO-COVID randomized clinical trial was conducted in 34 ICUs in France and included 711 patients with respiratory failure due to COVID-19 and a ratio of partial pressure of arterial oxygen to fraction of inspired oxygen equal to or below 200 mm Hg. It was an ancillary trial of the ongoing original SOHO randomized clinical trial, which was designed to include patients with acute hypoxemic respiratory failure from all causes. Patients were enrolled from January to December 2021; final follow-up occurred on March 5, 2022.
INTERVENTIONS: Patients were randomly assigned to receive high-flow oxygen (n = 357) or standard oxygen delivered through a nonrebreathing mask initially set at a 10-L/min minimum (n = 354).
MAIN OUTCOMES AND MEASURES: The primary outcome was mortality at day 28. There were 13 secondary outcomes, including the proportion of patients requiring intubation, number of ventilator-free days at day 28, mortality at day 90, mortality and length of stay in the ICU, and adverse events.
RESULTS: Among the 782 randomized patients, 711 patients with respiratory failure due to COVID-19 were included in the analysis (mean [SD] age, 61 [12] years; 214 women [30%]). The mortality rate at day 28 was 10% (36/357) with high-flow oxygen and 11% (40/354) with standard oxygen (absolute difference, -1.2% [95% CI, -5.8% to 3.4%]; P = .60). Of 13 prespecified secondary outcomes, 12 showed no significant difference including in length of stay and mortality in the ICU and in mortality up until day 90. The intubation rate was significantly lower with high-flow oxygen than with standard oxygen (45% [160/357] vs 53% [186/354]; absolute difference, -7.7% [95% CI, -14.9% to -0.4%]; P = .04). The number of ventilator-free days at day 28 was not significantly different between groups (median, 28 [IQR, 11-28] vs 23 [IQR, 10-28] days; absolute difference, 0.5 days [95% CI, -7.7 to 9.1]; P = .07). The most common adverse events were ventilator-associated pneumonia, occurring in 58% (93/160) in the high-flow oxygen group and 53% (99/186) in the standard oxygen group.
CONCLUSIONS AND RELEVANCE: Among patients with respiratory failure due to COVID-19, high-flow nasal cannula oxygen, compared with standard oxygen therapy, did not significantly reduce 28-day mortality.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04468126.
参考来源
- Frat JP, Quenot JP, Badie J, et al. Effect of High-Flow Nasal Cannula Oxygen vs Standard Oxygen Therapy on Mortality in Patients With Respiratory Failure Due to COVID-19: The SOHO-COVID Randomized Clinical Trial. JAMA. 2022. PMID: 36166027. doi:10.1001/jama.2022.15613
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。